Active ingredient
- finerenone
Legal Category
POM: Prescription only medicine
POM: Prescription only medicine
The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. It is written for patients and gives information about taking or using a medicine. It is possible that the leaflet in your medicine pack may differ from this version because it may have been updated since your medicine was packaged.
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.
Below is a text only representation of the Patient Information Leaflet. The original leaflet can be viewed using the link above.
The text only version may be available in large print, Braille or audio CD. For further information call emc accessibility on 0800 198 5000. The product code(s) for this leaflet is: PLGB 00010/0751 .
Kerendia 10 mg film coated tablets
Due to regulatory changes, the content of the following Patient Information Leaflet may vary from the one found in your medicine pack. Please compare the 'Leaflet prepared/revised date' towards the end of the leaflet to establish if there have been any changes.
If you have any doubts or queries about your medication, please contact your doctor or pharmacist.
Package leaflet: Information for the patient
Kerendia 10 mg film-coated tablets
Kerendia 20 mg film-coated tablets
finerenone
▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
What is in this leaflet
1. What Kerendia is and what it is used for
2. What you need to know before you take Kerendia
3. How to take Kerendia
4. Possible side effects
5. How to store Kerendia
6. Contents of the pack and other information
1. What Kerendia is and what it is used for
Kerendia contains the active substance finerenone. Finerenone works by blocking the action of certain hormones (mineralocorticoids) that can damage your kidneys and heart.
Kerendia is used for the treatment of adults with chronic kidney disease (stage 3 and 4 with abnormal presence of the protein albumin in the urine) associated with type 2 diabetes.
Chronic kidney disease is a long-term condition. Your kidneys keep getting worse at removing waste and fluids from your blood.
Type 2 diabetes is when your body cannot keep your blood sugar levels normal. Your body does not produce enough of the hormone insulin or cannot use the insulin properly. This leads to a high level of sugar in your blood.
2. What you need to know before you take Kerendia
Do not take Kerendia if you
Warnings and precautions
Talk to your doctor or pharmacist before taking Kerendia if you have
Blood tests
These tests check your potassium level and how your kidneys are working.
Using the results of your blood tests, your doctor decides whether you can start to take Kerendia.
After 4 weeks of taking Kerendia, you will have more blood tests.
Your doctor may test your blood at other times, for example while you are taking certain medicines.
Children and adolescents
Do not give this medicine to children and adolescents under 18 years because it is not known yet whether it is safe and effective in this age group.
Other medicines and Kerendia
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Your doctor will tell you which medicines you can take. Your doctor may need to test your blood to make sure.
You must not take medicines that belong to the group of ‘strong CYP3A4 inhibitors,’ while taking Kerendia (see section 2 “Do not take Kerendia…”).
Talk to your doctor or pharmacist if you are taking other medicines while taking Kerendia, especially
Kerendia with food and drink
Do not eat grapefruit or drink grapefruit juice as long as you take Kerendia.
If you do, you may get too much finerenone in your blood. You may have more side effects (possible side effects are listed in section 4).
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Pregnancy
You should not take this medicine during pregnancy unless your doctor states it is clearly necessary. There might be a risk to your unborn baby. Your doctor will discuss that with you.
You should use reliable birth control if you are able to become pregnant. Your doctor will explain to you what type of birth control you can use.
Breast-feeding
You should not breast-feed while taking this medicine. It may harm your baby.
Driving and using machines
Kerendia has no effect on your ability to drive or use machines.
Kerendia contains lactose
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
Kerendia contains sodium
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’.
3. How to take Kerendia
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
How much you have to take
The recommended and the maximum daily dose of this medicine is 1 tablet of 20 mg.
Your doctor may decide on changes in your treatment after testing your blood. See “Blood tests” in section 2 for more information.
How to take this medicine
Kerendia is taken by mouth. Take Kerendia at the same time every day. This makes it easier for you to remember.
Swallow the tablet whole.
If you cannot swallow the tablet whole, you can crush it.
If you take more Kerendia than you should
Talk to your doctor or pharmacist if you think you have taken too much of this medicine.
If you forget to take Kerendia
If you forget to take your tablet at your regular time that day
If you miss a day
Do not take 2 tablets to make up for a forgotten tablet.
If you stop taking Kerendia
Only stop taking Kerendia if your doctor has told you.
Your doctor may decide this after testing your blood.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Side effects that your doctor may see in your blood test results
very common (may affect more than 1 in 10 people)
common (may affect up to 1 in 10 people)
uncommon (may affect up to 1 in 100 people)
Other side effects
common (may affect up to 1 in 10 people)
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
5. How to store Kerendia
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the blister, bottle label and carton after EXP. The expiry date refers to the last day of that month.
This medicine does not require any special storage conditions.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
6. Contents of the pack and other information
What Kerendia contains
What Kerendia looks like and contents of the pack
Kerendia 10 mg film-coated tablets (tablets) are pink and oval-oblong, 10 mm long and 5 mm wide, marked ‘10’ on one side and ‘FI’ on the other side.
Kerendia 20 mg film-coated tablets (tablets) are yellow and oval-oblong, 10 mm long and a 5 mm wide, marked ‘20’ on one side and ‘FI’ on the other side.
Kerendia is available in cartons containing
Not all pack sizes may be marketed.
Marketing Authorisation Holder
Manufacturer
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
This leaflet was last revised in 02/2022.
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu.
For UK (Great Britain)
Marketing Authorisation Holder:
GB-NI v001_0
400 South Oak Way, Reading, Berkshire, RG2 6AD
+44 (0)118 206 3000